TABLE 2.

Inhibitory activities of PRO140-based inhibitors against divergent HIV-1 subtypes^a

Pseudovirus	Subtype	Tropism	Mean IC50 ± SD (nM)
			2P23	PRO 140	PRO140SC	2P23-PRO140SC	m36.4-PRO140
PVO	B	CCR5	6.673 ± 1.869	9.652 ± 3.825	12.680 ± 2.005	0.037 ± 0.009	0.857 ± 0.335
SC422661.8	B	CCR5	1.327 ± 0.202	6.086 ± 1.449	21.019 ± 1.991	0.022 ± 0.005	1.317 ± 0.502
JRFL	B	CCR5	8.436 ± 0.560	5.052 ± 0.199	20.011 ± 2.174	0.064 ± 0.048	0.067 ± 0.008
SF162	B	CCR5	4.011 ± 0.604	1.149 ± 0.376	2.348 ± 0.516	0.057 ± 0.018	0.558 ± 0.158
CNE4	B′	CCR5	2.424 ± 0.531	3.052 ± 0.946	6.562 ± 2.233	0.124 ± 0.034	0.230 ± 0.127
CNE6	B′	CCR5	1.182 ± 0.264	2.434 ± 0.456	4.355 ± 1.499	0.041 ± 0.009	0.132 ± 0.076
CNE9	B′	CCR5	0.998 ± 0.090	3.737 ± 1.177	6.189 ± 3.038	0.049 ± 0.010	0.250 ± 0.077
CNE11	B′	CCR5	3.231 ± 0.145	4.361 ± 1.411	11.328 ± 2.680	0.233 ± 0.067	0.242 ± 0.133
CNE14	B′	CCR5	3.270 ± 0.257	3.523 ± 1.219	2.970 ± 0.467	0.184 ± 0.021	0.180 ± 0.079
CNE57	B′	CCR5	1.041 ± 0.033	0.342 ± 0.053	0.764 ± 0.278	0.034 ± 0.011	0.086 ± 0.004
43–22	B′	CCR5	2.664 ± 0.155	1.642 ± 0.642	3.050 ± 0.562	0.027 ± 0.005	2.601 ± 0.298
B01	B′	CCR5	1.203 ± 0.123	5.260 ± 1.861	12.153 ± 6.646	0.082 ± 0.012	0.793 ± 0.189
CAP45.2.00.G3	C	CCR5	3.148 ± 0.312	5.099 ± 0.957	5.452 ± 0.746	0.054 ± 0.027	2.313 ± 2.098
Du156	C	CCR5	1.364 ± 0.297	11.918 ± 3.844	29.490 ± 9.158	0.029 ± 0.007	0.696 ± 0.084
AE03	A/E	CCR5	1.888 ± 0.088	1.847 ± 0.509	4.635 ± 0.279	0.038 ± 0.008	4.613 ± 1.287
CH64.20	B/C	CCR5	0.380 ± 0.009	10.567 ± 3.302	22.698 ± 6.418	0.035 ± 0.014	0.629 ± 0.247
CH70.1	B/C	CCR5	6.752 ± 1.637	2.457 ± 0.746	3.102 ± 0.440	0.075 ± 0.013	0.897 ± 0.283
CH110.2	B/C	CCR5	1.683 ± 0.267	13.329 ± 2.703	51.716 ± 12.863	0.049 ± 0.016	0.546 ± 0.055
CH120.6	B/C	CCR5	3.538 ± 0.305	9.829 ± 3.163	24.427 ± 16.281	0.152 ± 0.063	1.533 ± 0.675
Mean			2.424	4.361	12.892	0.073	0.976

^a The experiments were performed in triplicate and repeated three times. Data are expressed as means ± standard deviations (SDs).